p53 Immunohistochemistry in Ovarian Cancer: Reading the Aberrant Pattern

Why p53 Matters in Ovarian Pathology

Few immunostains carry as much diagnostic weight in gynecologic pathology as p53. The reason is biological. Mutation of TP53 is the defining molecular event of ovarian high-grade serous carcinoma (HGSC), present in about 99% of these tumors (169/171 in one sequenced series) and considered a near-obligate feature of the diagnosis [1][2][3][4]. That's a tight genotype-phenotype relationship, and it's exactly what makes the surrogate immunostain so useful at the microscope.

The p53 protein is a tumor suppressor that normally sits at low, tightly regulated levels in the nucleus. When TP53 is functioning as intended, the protein turns over quickly and stays scarce. Mutations disrupt that equilibrium in two broadly different ways, and, this is the key point, both of them are visible by immunohistochemistry (IHC) as deviations from the normal wild-type staining. We aren't sequencing the gene when we run p53 IHC. We're inferring its status from a protein pattern that behaves as a reliable stand-in for the underlying mutation [2][3].

How the Test Is Performed

p53 is assessed by IHC on formalin-fixed, paraffin-embedded (FFPE) tissue, the same blocks used for routine histology. No special specimen handling beyond good fixation is required, but preanalytics still matter. Underfixation, prolonged cold ischemia, or overdecalcified tissue can degrade nuclear antigenicity and muddy interpretation, so the usual FFPE discipline applies.

The interpretation is pattern-based rather than a simple positive-or-negative call, and getting this right is where experience shows. Three staining phenotypes are recognized:

• Diffuse strong overexpression, nearly all tumor nuclei show intense staining. This corresponds to missense mutations that stabilize an abnormal, accumulating protein.
• Complete absence (null pattern), no tumor nuclear staining at all, reflecting truncating or frameshift mutations that produce no detectable protein.
• Wild-type pattern, heterogeneous, variable-intensity nuclear staining across the tumor. This is the normal, non-aberrant result.

Both the overexpression and null phenotypes count as aberrant (mutant-pattern) staining [1][2][3][4]. The wild-type pattern does not.

In practice, the null pattern is the one most likely to trip up a trainee. Absent staining only means something if the assay worked, and the safeguard is the internal control: non-neoplastic cells, stromal fibroblasts, inflammatory cells, normal epithelium, should show scattered wild-type staining. If those cells stain and the tumor doesn't, you have a genuine null result. If nothing in the section stains, you can't distinguish a true null from a failed run, and the case has to be repeated or interpreted with real caution [4]. I've seen more than one "null" tumor turn out to be a fixation problem once the control was scrutinized.

What Each Result Means

An aberrant/mutant pattern, whether diffuse overexpression or complete null, supports a TP53-altered tumor. In the appropriate morphologic and immunophenotypic context, that pushes the diagnosis toward HGSC [1][2][3][4].

A wild-type pattern carries diagnostic weight of its own, and this is where p53 earns its place beyond confirming HGSC. By ICCR expert-consensus guidance, a serous tumor that is WT1-positive, a marker of serous lineage, but shows wild-type p53 argues against high-grade serous carcinoma and supports low-grade serous carcinoma (LGSC) instead [1][4]. LGSC is driven by MAPK-pathway alterations rather than TP53 mutation, so a preserved wild-type p53 pattern fits its biology [5]; the performance of this WT1/p53 combination for discriminating HGSC from LGSC has not been quantified in a primary accuracy study. Morphology should always be the anchor, but p53 frequently tips a difficult case one way or the other.

Why the HGSC-versus-LGSC Distinction Matters

This is not a semantic subtyping exercise. HGSC and LGSC behave like different diseases, and the diagnostic call informs which drug classes are even biologically relevant.

HGSC is characteristically responsive to platinum-based chemotherapy, platinum sensitivity is one of its clinical hallmarks. Its TP53-mutant, genomically unstable biology also situates it within the group of tumors where homologous-recombination status becomes clinically meaningful, and where PARP-inhibitor therapy is a relevant drug class to consider in the appropriate molecular context. Establishing an HGSC diagnosis, with aberrant p53 as supporting evidence, is what opens that whole line of reasoning.

LGSC sits at the other end. It's characteristically more indolent but comparatively resistant to conventional platinum chemotherapy, and its dependence on MAPK signaling is why MEK-pathway, directed agents are the drug class of biological interest here rather than the platinum/PARP framework relevant to HGSC [5]. So a WT1-positive serous tumor with wild-type p53 doesn't get a different label, it points toward an entirely different therapeutic universe.

To be explicit about scope: p53 IHC informs eligibility considerations for these drug classes by helping establish the tumor subtype; it does not by itself dictate any individual patient's treatment, which remains a clinical decision integrating stage, molecular testing, and the whole picture.

Caveats and What's Still Evolving

A few limitations should be named honestly. p53 IHC is a surrogate. It performs well against sequencing, in the validation series the aberrant-pattern call matched TP53 mutation status with an accuracy of 0.94, rising to 0.97 once discordant cases were re-reviewed (sensitivity ~0.96, specificity ~1.00), but it isn't infallible: certain in-frame deletions or splice-site mutations can occasionally produce staining that looks wild-type despite an underlying TP53 alteration, and rare cytoplasmic-only patterns exist that don't fit the tidy three-category scheme [2][3]. When the stain and the morphology disagree, a tumor that looks unmistakably high-grade serous but reads wild-type, that's the situation where reflex molecular confirmation of TP53 status is the right move rather than forcing the case into a category [2][3].

Interpretation is also observer-dependent at the margins. The line between "heterogeneous wild-type" and early diffuse overexpression can be subjective, and adequate internal controls remain non-negotiable for calling a null result with confidence.

Used carefully, though, p53 remains one of the highest-yield stains we run. It's fast, cheap, applicable to routine FFPE, and grounded in one of the cleanest genotype-phenotype relationships in solid-tumor pathology [1][2][3][4]. The practical takeaway: trust the pattern, always check the control, and know when a discordant case has earned a molecular second opinion.

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
2. Kuhn E, et al. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. Journal of Pathology; 2016. PMCID: PMC4696053.
3. Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247, 258. doi:10.1002/cjp2.53. PMID 27840695.
4. McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovarian carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28(8):1101, 1122. PMID 26089092.
5. Grisham RN, Vergote I, Banerjee S, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023;33(9):1331, 1344. PMID 37591609.